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Objective. Glass ionomer cements (GICs) are a versatile material, offering the opportunity for
ion  exchange with the oral environment. The aim of this study was to develop a GIC that
delivers a controlled, rechargeable dose of chlorhexidine (CHX) over an extended period
without compromising mechanical properties.
Methods. GICs were supplemented with ﬁnely milled particles of chlorhexidine hexam-
etaphosphate (CHX-HMP). CHX release into artiﬁcial saliva was measured over 660 days,
and recharge with CHX and CHX-HMP was investigated. Mechanical properties were inves-
tigated, and an agar diffusion test was carried out to assess antimicrobial properties using
Streptococcus mutans and Scardovia wiggsiae.
Results. Dose-dependent CHX release was observed, and this was ongoing at 660 days. Com-
pared  with related studies of GICs containing CHX-HMP, the ﬁne, dry particles resulted in
fewer  adverse effects on mechanical properties, including tensile, compressive and biaxial
ﬂexural strength, with 1% CHX-HMP GICs indistinguishable from control specimens. TheGICs  could be recharged with CHX using both a conventional CHX digluconate solution
comparable to commercial mouthrinses, and a suspension of CHX-HMP of equivalent con-
centration. Recharging with CHX digluconate increased subsequent CHX release by 50%
compared with no recharge, and recharging with CHX-HMP increased subsequent CHX
release by 100% compared with no recharge. The GICs inhibited growth of St. mutans and Sc.
wiggsiae in a simple agar diffusion model.
Abbreviations: BFS, biaxial ﬂexural strength; CHX, chlorhexidine; CS, compressive strength; DTS, diametral tensile strength; GIC, glass
onomer cement; HMP, hexametaphosphate.
∗ Corresponding author at: Bristol Dental School, University of Bristol, Lower Maudlin St, Bristol BS1 2LY, UK.
E-mail  address: m.e.barbour@bristol.ac.uk (M.E. Barbour).
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Signiﬁcance. These materials, which provide sustained CHX release over clinically relevant
timescales, may ﬁnd application as a restorative material intended to inhibit secondary
caries as well as in temporary restorations and ﬁssure sealants.
©  2018 The Academy of Dental Materials. Published by Elsevier Inc. This is an open access
nderarticle u
1.  Introduction
Glass ionomer cements (GICs) are a mainstay of mod-
ern dentistry. Their uses include temporary and permanent
restorations, lining and luting materials, ﬁssure sealants
and in atraumatic restorative therapy. Although GICs exhibit
ﬂuoride release, and antimicrobial effects of this can be
demonstrated in vitro, the data in support of an anticariogenic
effect in vivo is inconclusive [1–3]. Nevertheless, a bioactive
material that participates in ion exchange with its local envi-
ronment offers an adaptable vehicle for delivery of other
useful molecules to the locale of a restoration.
Chlorhexidine (CHX) is a broad-spectrum antimicrobial in
widespread use as a topical agent. It owes its antimicrobial
properties to membrane disruption and is efﬁcacious against
a wide range of microbes including those implicated in caries.
CHX in commercial products is typically present as the CHX
digluconate salt which is highly soluble and thus has poor
substantivity, usually providing only short term antimicrobial
function before it is depleted. CHX concentrations in saliva
fall rapidly after an oral rinse, with 90% of the initially retained
CHX cleared from the mouth within 6 h and 98% cleared within
12 h [4]. One product used for treatment of periodontal disease
provides sustained CHX release, but 80% of the CHX is released
within the ﬁrst 2 days, with a much lower release over the
following 3–4 weeks [5].
Owing to the useful antimicrobial functionality of CHX,
coupled with its low cost and well-understood pharmaco-
logical properties, there have been attempts to incorporate
CHX into dental materials, including GICs. GICs supplemented
with CHX diacetate and CHX digluconate inhibited growth of
oral microbes Streptococcus mutans and Lactobacillus acidophilus,
but the antimicrobial effects were sustained for only 40–90
days, with no bactericidal effect observed after this time [6]. In
another study where GIC was doped with CHX digluconate and
antimicrobial efﬁcacy again assessed using St. mutans and L.
acidophilus, there was an exponential decay of the zone of inhi-
bition over the ﬁrst 30 days [7]. These short-term antimicrobial
effects may be explained by the release proﬁles of soluble
CHX from GICs doped with these conventional salts, which
show a high initial release which rapidly diminishes leaving
little or no sustained release [8]. A recent report of core–shell
microparticles containing CHX chloride salts reveals potential
for graduate release of CHX, although this study only probed
CHX release to a maximum of 430 h (18 days) [9]. Supplementa-
tion with these CHX salts has also been found to be associated
with a negative impact on mechanical properties [6,10–12].
More recently, some attempts have been made to incorporate
CHX when loaded into particles that may facilitate gradual
rather than rapid release, and there has been some success the CC BY license (http://creativecommons.org/licenses/by/4.0/).
in this, but still the CHX release was heavily front loaded and
decayed rapidly after the ﬁrst 1–3 days [13].
Although in vivo studies of these experimental materials
are rare, there are a few small studies of note. Supplemen-
tation of a resin-modiﬁed GIC with 1.25% CHX digluconate
resulted in elimination of St. mutans populations following
indirect pulp treatment in vivo [14], and incorporation of CHX
digluconate into a GIC reduced microbial counts in cavities
in ﬁrst primary molars in 6–9 year olds, although the CHX
digluconate GICs also exhibited a higher failure rate than
the controls [15]; similar results were observed in a study of
CHX digluconate doped GICs in children receiving atraumatic
restorative therapy, where the CHX GICs resulted in reduced St.
mutans counts at 7 days but not 3 or 12 months after placement
[16]. These tentative ﬁndings highlight the potential bene-
ﬁt of CHX-functionalised restorative materials as well as the
challenges, in that the other properties of the GIC are often
compromised by the new component.
We have recently reported a novel salt of CHX: CHX-
hexametaphosphate (CHX-HMP) [17]. CHX-HMP has a much
lower solubility than CHX digluconate or CHX diacetate, and
when in or on biomaterials, can confer a sustained release of
CHX [18]. We  have described a pilot study demonstrating the
use of manually ground CHX-HMP as a ﬁller for GICs [19], and
another where the CHX-HMP was incorporated into a GIC as
a viscous paste formulation [20]. In the ﬁrst study [19], large
clusters of CHX-HMP particles were used, and this had adverse
effects on the mechanical properties; furthermore, another
limitation of that study was the short time over which CHX
release from the prototype cements was recorded, and the
large particle size would have had a detrimental effect on this
CHX release. In the second report [20], the incorporation of the
particles in a wet aqueous paste resulted in deterioration of
the mechanical properties when the substitution of CHX-HMP
was at 0.34% by mass or greater, although the CHX  release
was  improved on the earlier approach, being sustained for
at least 14 months. The aim of the study described here was
to investigate the use of CHX-HMP particles as GIC ﬁllers but
incorporating a mechanical milling process resulting in much
smaller CHX-HMP ﬁller particles. The hypothesis was that
the smaller particle size and thus larger speciﬁc surface area
would create a more  sustained CHX release coupled with fewer
adverse effects on mechanical properties. Furthermore, given
that any antimicrobial incorporated into a biomaterial has a
ﬁnite duration of release, the capacity of these materials to be
“recharged” with CHX, in analogy to the well-known ﬂuoride
recharge phenomenon, was investigated. A simple microbi-
ological test was incorporated into the study to determine
whether CHX release from the prototype GICs had an effect on
two cariogenic bacteria in an agar diffusion test. The conven-
tional and well-characterised St. mutans was selected for the
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est, as well as Scardovia wiggsiae, a recently recognised anaer-
bic pathogen associated with aggressive childhood caries
21,22].
.  Methods
.1.  Preparation  of  CHX-HMP  ﬁller  particles
00 mL  10 mM solutions of each of CHX digluconate and
odium HMP  (Sigma Aldrich, Gillingham, UK) were prepared
n deionised water and were combined in a glass beaker under
mbient laboratory conditions. The resulting aqueous suspen-
ion of CHX-HMP was stirred vigorously for approximately
 min, then 30 mL  1 M potassium chloride was added and
tirred for a further minute. The suspension was stored with-
ut disturbing for 24 h, allowing the precipitate to sediment
t the base of the container. The supernatant was gently dis-
arded leaving a concentrated suspension of the precipitate,
hich was then centrifuged at 4760 g for 30 min. The super-
atant was again discarded and the pellet dried at ambient
emperature under air extraction for 24 h, then removed from
he centrifuge tubes. 100 g total mass of dried CHX-HMP pel-
ets prepared in this way was placed into a cylindrical ceramic
ill of 80 mm diameter and 70 mm height containing ceramic
alls of sizes 12.5–20.5 mm (Pascal Engineering Company Ltd.,
rawley, UK), and this was placed on a rolling platform for
 h. The mill was opened every hour and particles dislodged
rom the internal walls. The resulting powder was passed
hrough a coarse sieve and examined using scanning electron
icroscope (SEM). The speciﬁc surface area was measured
y nitrogen adsorption following outgassing for 48 h at 30 ◦C
nder vacuum. Elemental microanalysis (CHNP) was used to
onﬁrm the composition of the precipitate; CHX-HMP was
repared as described above and analysed for C, H, N and P
Microanalytical Laboratory, School of Chemistry, University
f Bristol).
.2.  Preparation  of  specimens  (elution,  DTS,  CS)
iamond CarveTM GIC (Kemdent, Purton, UK) was used as
he base material to create experimental cements. This com-
ercial GIC comprises a powder consisting of alumina-silica
ased glass ﬁller particles which also contain calcium ﬂu-
ride and other minor salt components and freeze-dried
oly(vinyl)phosphonic acid, and a liquid, which contains poly-
crylic and tartaric acids.
For the prototype GICs, CHX-HMP particles were substi-
uted for the glass component in the GIC powder at 0, 1, 2,
 and 10% by mass. All dopings were tested for each parame-
er below, unless otherwise speciﬁed. The CHX-HMP particles
ere mixed with the GIC powder in the ball mill for 10 min
s described above to ensure homogeneous incorporation of
he components. This powder was then mixed at a 4:1 ratio
y mass with the GIC liquid according to the manufacturers’
nstructions. Mixing was completed in 40–50 s and packing
nto the moulds took a further 10 s, such that the process of
reating the specimens was complete within 60 s.
GICs were packed, using a stainless steel dental spatula,
nto stainless steel moulds with dimensions dependent on 0 1 8 ) 1717–1726 1719
the purpose of the speciﬁc specimen. Dimensions were: 6 mm
height and 4 mm diameter for compressive strength determi-
nation; 4 mm height and 6 mm diameter for measurement
of diametral tensile strength, release of soluble CHX, and
antimicrobial testing; 2 mm height and 15 mm diameter for
determination of ﬂexural strength. The moulds were lined
with a thin layer of petroleum jelly to aid removal of the set
cement. Immediately after packing, the moulds were placed
between two sheets of acetate and a 2 kg weight placed on
top of the specimens on a ﬂat surface to ensure even distribu-
tion of the cement. After 5 min  the specimens, except those
for biaxial ﬂexural strength testing, were ground on the two
ﬂat surfaces using a P120 grit SiC disc and were then placed
into small, sealed plastic vessels containing wet tissue paper
packed into the lid to achieve 100% humidity without direct
contact with water. Specimens were stored at 37 ◦C for 7 days
prior to testing.
2.3.  Compressive  strength  (CS)  testing
CS was measured by applying a compressive force to the
ﬂat surface of the cylindrical specimens (6 mm height, 4 mm
diameter) using a universal testing machine (Instron, Buck-
inghamshire, UK) with cross-head speed of 1 mm/min  and
recording the load at fracture. Specimen dimensions were
measured three times using a digital micrometer. Load at frac-
ture LF was used with diameter D to calculate CS according to
the relationship CS = 4L/D2. Specimens were examined after
fracture for evidence of ﬂaws on the internal or external sur-
faces and ﬂawed specimens were rejected. n = 24 specimens
per group were used. Data were analysed using a one-way
ANOVA followed by a Tukey Honestly Signiﬁcant Difference
post-hoc test at  ˛ = 0.05.
2.4.  Diametral  tensile  strength  (DTS)  testing
DTS was measured by applying a compressive force to the
curved sides of the cylindrical specimen (4 mm height, 6 mm
diameter) using a universal testing machine (Instron, Buck-
inghamshire, UK) with cross-head speed of 1 mm/min  and
recording the load at fracture. Specimen dimensions were
measured three times using a digital micrometer. The load at
fracture LF was used in conjunction with the average diameter
D and height h of the specimens to calculate DTS according
to the relationship DTS = 2L/Dh. Specimens were examined
after fracture for evidence of ﬂaws on the internal or external
surfaces and data from specimens found to be ﬂawed were
rejected. Data were analysed using a one-way ANOVA fol-
lowed by a Tukey Honestly Signiﬁcant Difference post-hoc test
at  ˛ = 0.05. As well as freshly prepared specimens (n = 24 per
group), the specimens that were subjected to the long-term
CHX elution experiments were also tested for DTS to ascer-
tain whether strength deteriorated after long-term exposure
to artiﬁcial saliva (n = 15 per group).
2.5.  Biaxial  ﬂexural  strength  (BFS)  testingBFS was measured in a ball-on-ring conﬁguration, by applying
force to the ﬂat surfaces of the specimens (15 mm diameter,
2 mm height) using a universal testing machine with cross-
 s 3 41720  d e n t a l m a t e r i a l
head speed of 1 mm/min  (Instron, Buckinghamshire, UK) and
recording the load at failure. The circular discs were positioned
on a 10 mm diameter knife-edge annulus with a thin sheet
of rubber between the annulus and the sample. Specimens
were centrally loaded with a spherical 4 mm diameter stain-
less steel ball indentor. BFS (in MPa)  was calculated according
to the relationship,
BFS = LF
h2
{
(1 + )
[
0.484ln
(
a
h
)
+ 0.52
]
+ 0.48
}
where LF = measured load at fracture, a = radius of knife edge
support in mm,  h = specimen thickness measured at point of
fracture in mm and  = Poisson’s ratio (0.30). n = 24 specimens
per group were prepared, and specimens were rejected if there
were any visible ﬂaws.
2.6.  Measurement  of  elution  of  soluble  CHX
GIC specimens were weighed using a precision balance then
placed in individual cuvettes transparent to ultraviolet light
(Z637157; Sigma–Aldrich, Gillingham, UK). 1.5 mL  artiﬁcial
saliva was added to each cuvette. The artiﬁcial saliva was
composed of 0.9 mM CaCl2, 0.2 mM MgCl2, 4.0 mM KH2PO4,
30.0 mM KCl, 20.0 mM HEPES buffer, titrated to pH of 6.8 [23].
The cuvettes were sealed with tightly-ﬁtting lids (SEMA2533;
VWR, Lutterworth, UK) and then placed onto an orbital shaker
(SSM1, Stuart, Staffordshire, UK) at 150 rpm and readings
taken initially once a day, and less frequently as CHX release
decelerated. Artiﬁcial saliva was refreshed at two-week inter-
vals to avoid any decrease in CHX release that could be
attributed to saturation of the artiﬁcial saliva with respect to
CHX salts. Adsorption of light at wavelength 255 nm was mea-
sured at regular intervals and calibration standards of 5–50 M
CHX used as references to establish CHX release from the GICs
into the artiﬁcial saliva [24]. This was converted to moles
CHX released per unit surface area for each specimen and
normalised by subtracting the mean reading for the 0% substi-
tution, correcting for any systematic error due to background
readings. n = 15 specimens per group were used. Cuvettes were
inspected carefully at each reading and, in the rare event that
leakage occurred, the specimen was discarded. CHX elution
was measured for 660 days.
2.7.  Investigation  of  CHX  recharge  capacity  of  GICs
Specimens were prepared as described above and subjected
to CHX elution measurements as described in the previous
section, with modiﬁcation to permit the investigation of the
capacity for recharge and subsequent release of the CHX.
Three sets of specimens (n = 15 each of 0, 1, 2, 5, 10% CHX-HMP
for each set) were stored in artiﬁcial saliva and CHX release
was assessed using UV spectrophotometry as described above.
Every 4 weeks the specimens were removed from the arti-
ﬁcial saliva and were immersed in one of three “recharge”
preparations: deionised water (negative control), 2.2 mM CHX
digluconate (“CHX”) and a CHX-HMP suspension containing
the equivalent of 2.2 mM CHX (“CHX-HMP”). CHX release of the
three groups was assessed to determine whether the speci-
mens periodically exposed to CHX or CHX-HMP had a different
subsequent CHX release than those exposed only to water. ( 2 0 1 8 ) 1717–1726
Readings were converted to moles CHX released per unit
surface area for each specimen and normalised by subtract-
ing the mean reading for the 0% substitution. Cuvettes were
inspected carefully at each reading and, in the rare event that
leakage occurred, the specimen was discarded. CHX elution
was measured for 315 days.
2.8.  Assessment  of  antimicrobial  efﬁcacy
St. mutans GS-5 [25] was maintained in Brain Heart Infu-
sion broth supplemented with 0.5% (w/v) Yeast Extract (BHY)
and incubated for 16 h at 37 ◦C in a candle jar. Sc. wiggsiae
C1A 55 [26] was maintained in Tryptic Soy broth supple-
mented with 0.5% (w/v) Yeast Extract, 25 g/mL haemin and
5 g/mL menadione (TSBYHM) and incubated for 5 days at
37 ◦C anaerobically under N2:CO2:H2 (80:10:10). Bacterial cells
were harvested (5000 g, 7 min), washed and resuspended in
PBS at OD600 1.0 (approximately 2 × 108 cells/mL). Adjusted
cell suspensions (100 L) were spread evenly over BHY agar
plates (St. mutans) or fastidious anaerobe agar (FAA) plates (Sc.
wiggsiae), before placing GIC specimens (0 and 2% CHX-HMP)
(6 mm diameter, 4 mm height) onto the agar. These lawn  plates
were then incubated as before for 16 h (St. mutans) or 5 days (Sc.
wiggsiae), before zones of inhibition around the GIC specimens
were measured.
3.  Results
3.1.  Characterisation  of  CHX-HMP  ﬁller  particles
SEM images of the milled CHX-HMP particles are shown in
Fig. 1. The milled particles were polydisperse, with the most
common sizes in the 1–20 m range and some aggregates as
large as 50–150 m.  The speciﬁc surface area of the powder
as determined using BET was 1.55 m2 g−1 and no micropore
volume could be measured indicating a very low porosity. Ele-
mental microanalysis indicated that the composition of the
precipitate was 20% N, 40% C, 5.3% H and 8.6% P, which cor-
responds most closely to a composition of 3 CHX to 1 HMP
(theoretical values 21% N,  40% C, 4.9% H, 9.3% P). Given the
relative molecular masses of CHX and HMP  this indicates that
the CHX-HMP solid is approximately 76% CHX by mass.
3.2.  Compressive  strength  of  CHX-HMP  functionalised
cements
CS data are shown in Fig. 2 with error bars representing stan-
dard deviations. Rejection of specimens with internal voids,
imperfections or non-linear force-distance curves resulted in
ﬁnal n per specimen group of 17–22 (mean n = 18.6; initial
n = 24). According to the ANOVA and Tukey HSD test, there
was no statistically signiﬁcant difference between CS of con-
trol, 1% or 2% CHX-HMP specimens; 5% and 10% CHX-HMP had
signiﬁcantly lower CS; that is, substitutions up to and includ-
ing 2% had no impact of CS compared with control specimens,
whereas 5% or more  CHX-HMP had a negative impact on CS.
d e n t a l m a t e r i a l s 3 4 ( 2 0 1 8 ) 1717–1726 1721
Fig. 1 – Scanning electron micrographs showing ball-milled CHX-HMP ﬁller particles. Scale bars are a: 500 m;  b: 100 m; c:
50 m;  d: 10 m.  The particles are polydisperse, with typical sizes ranging from 1 to 20 m and some aggregates as large as
50–150 m.
Fig. 2 – Compressive strength of GIC specimens as a function of CHX-HMP substitution. Error bars represent standard
deviations. There was no statistically signiﬁcant difference between CS of control, 1% or 2% CHX-HMP specimens; 5% and
1 d 2%
3
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a0% CHX-HMP had signiﬁcantly lower CS than control, 1% an
.3.  Diametral  tensile  strength  of  CHX-HMP
unctionalised  cements
TS data are shown in Fig. 3 with error bars representing stan-
ard deviations. For specimens tested without aging, rejection
f specimens with internal voids, imperfections or non-linear
orce-distance curves resulted in ﬁnal n per specimen group
f 19–24 (mean n = 21.2; initial n = 24). For specimens tested
fter immersion in artiﬁcial saliva for 660 days, rejection of specimens.
specimens with internal voids, imperfections or non-linear
force-distance curves resulted in ﬁnal n per specimen group
of 8–14 (mean n = 11.2; initial n = 15).
According to the ANOVA and Tukey HSD test, the only sta-
tistically signiﬁcant differences in these data were between
unaged 2% and 10% CHX-HMP specimens, where 10% CHX-
HMP  had lower DTS than 2%, and between unaged 2% and
aged 2% CHX-HMP specimens, where the aged material had
lower DTS than the unaged material. That is, for unaged
1722  d e n t a l m a t e r i a l s 3 4 ( 2 0 1 8 ) 1717–1726
Fig. 3 – Diametral tensile strength of GIC specimens as a function of CHX-HMP substitution. Error bars represent standard
deviations. Dark grey: freshly prepared specimens after storage for 7 days; light grey: aged specimens after 660 days in
artiﬁcial saliva. The only statistically signiﬁcant differences were  between unaged 2% and 10% CHX-HMP specimens, where
10% CHX-HMP had lower DTS than 2%, and between unaged 2% and aged 2% CHX-HMP specimens, where the aged
material had lower DTS than the unaged material.
specimens substitutions up to and including 10% CHX-HMP
had no impact on DTS compared with control specimens, and
after aging one specimen group exhibited a reduction in DTS
but there were no differences among the groups of specimens
comparing all aged specimens.
3.4.  Biaxial  ﬂexural  strength  (BFS)  of  CHX-HMP
functionalised  cements
BFS data are shown in Fig. 4 with error bars representing stan-
dard deviations. Rejection of specimens with imperfections
resulted in ﬁnal n per specimen group of 22–24 (mean n = 23.0;
initial n = 24). According to the ANOVA and Tukey HSD test, the
1% CHX-HMP was indistinguishable from the control group,
whereas the others (2, 5 and 10% CHX-HMP) had lower BFS
than the control group.
Fig. 4 – Biaxial ﬂexural strength of GIC specimens as a function o
deviations. The control and 1% CHX-HMP formed one statisticall
CHX-HMP) formed a second group with signiﬁcantly lower BFS th3.5.  Elution  of  soluble  CHX  from  functionalised
cements
Elution of soluble CHX from CHX-HMP doped GICs is shown
in Fig. 5. A dose-dependent CHX release was seen, with the
total CHX released being related, although not directly pro-
portional, to the total CHX content of the material. The CHX
release had a smooth proﬁle and did not accelerate and decel-
erate over the period investigated, indicating that the frequent
changing of elution medium ensured that saturation was not
a factor in controlling the rate of CHX release.
3.6.  Investigation  of  CHX  recharge  capacity  of  GICsElution of soluble CHX from CHX-HMP doped GICs is shown
in Fig. 6. Specimens recharged with the 2.2 mM CHX solution
released more  CHX than negative controls exposed to DIW;
f CHX-HMP substitution. Error bars represent standard
y homogeneous group, whereas the others (2, 5 and 10%
an the control and 1% CHX-HMP specimens.
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Fig. 5 – Cumulative CHX release from GIC specimens as a function of CHX-HMP substitution, normalised to control
specimens (no CHX-HMP). The elution medium was changed frequently to ensure that at no time the degree of saturation
approached the limit of solubility of the CHX HMP  salt, ensuring sink conditions throughout.
Fig. 6 – Cumulative CHX release from GIC specimens as a function of CHX-HMP substitution and recharge medium,
normalised to control specimens. Specimens recharged with 2.2 mM CHX solution released on average 50% more  CHX than
negative controls (exposed to DIW). Specimens recharged with CHX-HMP suspension at the same equivalent total CHX
c e rec
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1oncentration released on average 33% more  CHX than thos
han negative controls.
n average 50% more  CHX was released by the CHX recharged
pecimens than the controls over the 315 day period. Spec-
mens recharged with CHX-HMP suspension at the same
quivalent total CHX concentration released more  CHX again
han the CHX solution recharged specimens; on average over
he 315 period specimens recharged with CHX-HMP released
3% more  CHX than those recharged with CHX solution and
00% more  CHX than negative controls.harged with CHX solution and on average 100% more  CHX
3.7.  Antimicrobial  efﬁcacy  of  functionalised  cements
Control GICs without CHX-HMP showed no remote or contact
inhibition of microbial growth with either St. mutans or Sc. wig-
gsiae. 2% CHX-HMP GICs resulted in both contact and remote
microbial inhibition of St. mutans, with an average 11.9 mm
zone of inhibition (5.7 mm as measured from the edge of the
GIC specimen). 2% CHX-HMP GICs inhibited growth of Sc. wig-
 s 3 41724  d e n t a l m a t e r i a l
gsiae but did not result in remote inhibition (i.e.  the inhibition
of microbial growth was restricted to the area of agar in direct
contact with the specimen).
4.  Discussion
Incorporation of dry, milled CHX-HMP particles into a com-
mercial GIC resulted in the release of aqueous CHX that was
still ongoing at 660 days for all specimen groups. There was a
dose response, with higher CHX-HMP dopings releasing more
CHX, although this was non-linear, as the total release at
660 days for 2, 5 and 10% CHX-HMP was 1.8x, 4.3x and 6.5x
that of the 1% CHX-HMP material respectively. The rate of CHX
release decelerated after approximately 150 days, and from
that time was close to constant until the conclusion of the
study.
The kinetics of CHX release are very different from those
observed in other CHX-doped GICs, where there is a rapid
decay of CHX release after the ﬁrst few days of measure-
ment. The fundamental difference is that most of the studies
described above utilise CHX digluconate and diacetate which,
owing to their solubility, dissipate rapidly in contact with
aqueous solutions. CHX-HMP has a much lower solubility than
CHX digluconate or diacetate and the rate of CHX release
is governed by kinetic factors (agitation of the surrounding
medium) and thermodynamic factors (degree of undersatura-
tion of the surrounding medium, which were effectively sink
conditions in this study as evidenced by the smooth proﬁle
where the 14 day medium changes were not detectable by an
acceleration in CHX release). Thus the release proﬁle is not
characterised by the “burst” release that has been observed in
all studies of CHX digluconate and CHX diacetate GICs.
Utilising the elemental analysis data it can be concluded
that the CHX-HMP solid is ∼72% CHX, and this enables calcu-
lation of the total CHX contained within the GIC specimens.
Given a specimen mass of 202 mg  taken from the mean of
152 specimens, this equates to a total content of CHX in the
specimens as 1%: 2.9 mol  CHX; 2%: 5.8 mol  CHX; 5%:
14.4 mol  CHX; 10%: 28.7 mol  CHX. At the end of the 660 day
period the total CHX released by the specimens was 1%:
0.027 mol  CHX; 2%: 0.049 mol  CHX; 5%: 0.115 mol  CHX; 10%:
0.175 mol  CHX. This indicates that the total CHX release over
the 660 day period for all four specimen groups was of the
order of 1% of the total CHX contained within the material.
It is likely that the CHX that was released was primarily from
the outer region of the specimen, where ion exchange with
the artiﬁcial saliva would most readily take place. It does indi-
cate that the CHX was far from depleted at the endpoint of the
study and that continued CHX release would have been likely
for a substantially longer time even without recharge. Further-
more, the volume of saliva and the perpetual undersaturation
reﬂects the conditions at the surface of the GIC that would
be exposed in the oral environment, and not that interface
which would be of most clinical interest, that is, the inter-
face between GIC and tooth tissue. At this location the ﬂuid
ﬂow would be very much less and therefore the CHX concen-
tration would likely reach a saturation that would decelerate
any further CHX release owing to the common ion effect. To
the extent that these observations can be used to infer clin- ( 2 0 1 8 ) 1717–1726
ical behaviour it is likely that the duration of CHX release in
these experiments underestimates the duration that would be
observed at the material-tooth interface in vivo.
The capacity to recharge CHX-containing GICs has not
previously been investigated. The data indicated that when
exposed to either CHX digluconate solution with a concen-
tration equivalent to that in widely used oral rinses, or a
CHX-HMP suspension with the same total CHX, subsequent
CHX release by the GICs was greater. This indicates that the
GIC can take up CHX from its environment, and subsequently
release it again in a reversible process. The aim of this part of
the study was to determine whether the longevity of the CHX
release could potentially be extended by periodic exposure to
an oral rinse containing CHX. It appears that this could be
effective, and furthermore, a rinse composed of a suspension
of CHX-HMP is likely to be more  effective, leading to greater
CHX release than the CHX digluconate solution. However, the
data must be interpreted with caution, since while GICs have
long been accepted to take up ﬂuoride from their environment,
this ability is now recognised to be short-lived, and is lost after
the ﬁrst month of maturation [27]. Therefore, further inves-
tigations regarding the recharge of GICs with chlorhexidine
will need to be carried out with more  mature specimens to
determine whether the same limitations apply.
A primitive assessment of antimicrobial efﬁcacy, the zone
of inhibition or agar diffusion method was adopted in this
study. The method has many  limitations but is commonly
used as a ﬁrst attempt to assess antimicrobial materi-
als, including dental restoratives. It is commonly used in
other ﬁelds to assess antimicrobial susceptibility of particu-
lar microbes. It is important to bear in mind, if comparing
different antimicrobials, that the remote effect (the “zone of
inhibition”) is affected not only by the interaction between
the microbe and the antimicrobial, but also by the ease by
which the antimicrobial can diffuse through the agar. CHX,
being a comparatively large molecule, diffuses through agar
less readily than some antiseptics.
The aim of the disc diffusion study was to take the ﬁrst
steps in assessing whether the CHX release from the proto-
type GICs was sufﬁcient to have an adverse effect on growth
of oral cariogenic microbes, whilst it is acknowledged that
more  sophisticated, multi-species models would be beneﬁcial
in future in ascertaining the optimal dose of CHX-HMP for a
given clinical indication. In this simple study, it was illustrated
that the 2% CHX-HMP doped specimens inhibited the growth
of both St. mutans and Sc. wiggsiae, with a greater effect on the
former microbe.
When adding materials such as CHX salts to GICs it is
important to consider the effect that the dissolution of the
salts may have on mechanical properties, and the higher the
concentration of material the greater the likelihood of an
adverse effect on properties such as strength. When adding
conventional CHX salts digluconate and diacetate, a dose
response of an adverse affect on strength is indeed observed,
although the threshold for a statistically signiﬁcant effect
varies from study to study and is likely to be affected by a
number of factors including sample size and means of incor-
porating the CHX. Turkun et al. [6] observed that 0.5% CHX
diacetate and 0.5, 1.25 and 2.5% CHX CHX had no adverse
effect on CS but higher concentrations of CHX diacetate did
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educe CS. There was a numerical reduction in DTS for 2.5%
HX diacetate and digluconate of ∼30% but this was not sta-
istically signiﬁcant; 0.5 or 1.25% had no effect on DTS either.
hluwalia observed similarly that 1% CHX diacetate had no
dverse effect on the CS or DTS of a GIC, but did not investi-
ate higher or lower concentrations [28]; whereas Mittal who
tilised concentrations of 1.5 and 3% CHX diacetate observed a
30% reduction in CS compared to unmodiﬁed GIC [29], while
uque observed no decrease in CS when adding 1.25 and 2.5%
HX digluconate to a GIC [30]. While it is therefore not possi-
le to draw a deﬁnitive conclusion as to what concentration
f CHX salts has a signiﬁcant (whether statistical or clinical)
ffect on strength, a likely explanation of the reduction in
S and DTS observed by some authors with higher concen-
rations may be explained Marti’s observation that increased
oncentration of CHX diacetate or digluconate is accompa-
ied by an increase in porosity [10] which is likely to reduce
trength.
The higher the substitution of CHX-HMP, the more  likely a
eleterious effect on the mechanical properties, with substitu-
ions of 5% or greater adversely affecting CS, and substitutions
f 2% or above adversely affecting BFS, although none signif-
cantly affected DTS. At the higher concentrations of 5 and
0%, the CS was 100 MPa which is the minimum CS stipu-
ated by the relevant ISO standard for restorative cements [31];
ower concentrations brought the strength more  comfortably
ithin the acceptable range at 130–150 MPa.  The threshold for
dverse effects on the mechanical properties of these materi-
ls appears therefore to be broadly comparable, or perhaps a
ittle higher, than that for more  soluble CHX salts, although it
ould be interesting to explore how these mechanical prop-
rties vary over time as the CHX is released from the various
IC materials.
It is considered encouraging that for the lower dopings of
HX-HMP the effects on the mechanical properties are mod-
rately small; should such materials become commercially
iable, it is plausible that other aspects of the formulation
ould be modiﬁed to compensate for this loss of strength.
n the other hand, these GIC materials could be considered
s prototypes for GIC-based ﬁssure sealants, where absolute
trength is of lesser importance and the local delivery of
ntimicrobial to the ﬁssure areas could be considered ben-
ﬁcial, and as temporary materials designed to stabilise the
egion before the deﬁnitive restoration is placed. However,
iven the calculations presented above regarding the propor-
ion of CHX released from the specimens, and the reﬂections
n relative ﬂuid ﬂow rate and therefore CHX saturation at the
ooth-tissue interface, it is plausible that even the lower con-
entrations of CHX-HMP used here may still offer sufﬁcient
HX release to operate as long-term restoratives without com-
romise to mechanical properties.
.  Summary
ICs have been developed which are supplemented with ﬁne,
illed, CHX-HMP particles. CHX release was sustained for
onsiderably longer and at a more  consistent rate than with
ny previous published studies, and with fewer adverse effects
n mechanical properties than many  formulations with short 0 1 8 ) 1717–1726 1725
lived and front-loaded CHX release. Earlier studies with CHX-
HMP  prepared in different ways have achieved long term CHX
release, for example ongoing release after over 400 days in
artiﬁcial saliva, but this was at the expense of mechanical
properties even using much smaller CHX-HMP dopings. The
materials presented in this manuscript may prove beneﬁcial
as technologies with the aim of inhibiting secondary caries
in mainstream restorative materials, as well as related mate-
rials such as temporary restorations and GIC-based ﬁssure
sealants.
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